LY6G6D (US20240190966A1 Biosimilar Antibody) 重組單克隆抗體是一種針對LY6G6D靶點，其靶點全稱為淋巴細(xì)胞抗原6復(fù)合體基因座蛋白G6d，同時存在Protein Ly6-D、巨核細(xì)胞增強基因轉(zhuǎn)錄物1蛋白等別名，對應(yīng)基因名稱包括LY6G6D、C6orf23、G6D、MEGT1及NG25。該抗體以重組人LY6G6D蛋白制備，具有高度特異性，可與人和食蟹猴（Macaca fascicularis）的LY6G6D蛋白發(fā)生特異性結(jié)合反應(yīng)，為跨物種研究提供了工具支持。 LY6G6D作為一種在特定免疫細(xì)胞及腫瘤組織中表達的蛋白分子，其相關(guān)抗體類似物的開發(fā)聚焦于腫瘤免疫治療及自身免疫性疾病等方向。臨床前研究顯示，靶向LY6G6D的單克隆抗體類似物可能通過調(diào)節(jié)免疫細(xì)胞活性、抑制腫瘤微環(huán)境中的免疫抑制信號或直接誘導(dǎo)腫瘤細(xì)胞凋亡等機制發(fā)揮治療作用。目前，該抗體類似物的研發(fā)正處于臨床前評價或早期臨床試驗階段，重點考察其藥代動力學(xué)特征、安全性及初步療效，為后續(xù)應(yīng)用于血液系統(tǒng)腫瘤、實體瘤等疾病的治療奠定基礎(chǔ)。 LY6G6D重組單克隆抗體主要用于LY6G6D蛋白的表達檢測、功能研究及相關(guān)信號通路分析。借助其對人和食蟹猴的種屬反應(yīng)性，研究人員可在細(xì)胞實驗（如、染色）及動物模型（如食蟹猴疾病模型）中特異性識別LY6G6D蛋白，探究其在免疫調(diào)節(jié)、細(xì)胞分化及腫瘤發(fā)生發(fā)展中的作用機制。此外，該抗體還可用于開發(fā)基于LY6G6D的診斷試劑，輔助疾病的早期篩查與預(yù)后評估，為基礎(chǔ)研究向臨床轉(zhuǎn)化搭建橋梁。

O95868

Lymphocyte antigen 6 complex locus protein G6d; Protein Ly6-D; Megakaryocyte-enhanced gene transcript 1 protein; LY6G6D; C6orf23; G6D; MEGT1; NG25

Human

Recombinant Human LY6G6D protein

Homo sapiens (Human)

Non-conjugated

Monoclonal

It differs from different batches. Please contact us to confirm it.

0.01M PBS，pH7.4

Liquid

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

In stock

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.